Home page

CARDIOPROGRESS
Foundation for the advancement of cardiology

Knowledge, observation, action

  РУС

Feedback

RU EN
  •  About Foundation 
  •  Scientific news 
  •   Events  
  •   Projects  
  •   Guidelines  
  •   Trials  
  •   Editorial activity  
  •   Archive  

European Society of Cardiology (ESC) Congress 2020.

 
 
 
 
 
 
 
 
 
 
 
 
 
Mini-Dose Edoxaban May Safely Cut AF Stroke Risk in Very Elderly 
 
ESC Guideline on Non ST-Elevation ACS
 
HOME-PE Trial Clarifies Which PE Patients to Treat at Home
 
First Randomized Trial Reassures on ACEIs, ARBs in COVID-19
 
Gut Bacteria Linked to Cardiovascular, Other Health Conditions
 
LoDoCo2: Added Steam for Colchicine as Secondary Prevention
 
Antihypertensive Treatment Beneficial at Normal BP Levels
 
Victory in HFpEF Again Evades ARNI Despite Hopeful Signals
RATE-AF Trial Boosts Digoxin for Rate Control in Permanent AF
 
DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
 
ATPCI: Trimetazidine Fizzles for Post-PCI Angina
 
Evolocumab Safe and Effective in Pediatric FH
 
New ESC/EACTS Guideline on Atrial Fibrillation
 
Aspirin Alone Preferred Antithrombotic Strategy After TAVI
 
EAST-AFNET 4: Early Rhythm Control in AF Gains New Life
 
EXPLORER Hints at Potential New Drug Option in Obstructive HCM
 
Empagliflozin's HFrEF Benefit Solidifies Class Effects
 
ESC 2020 Looks to Make Its Mark in 'New Era' of Virtual Meetings
 
 
 

Scientific news

  • Blood Pressure Variability Linked to Mortality in Patients With ANCA-Associated Vasculitis Among patients with antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis undergoing maintenance therapy, greater visit-to-visit systolic blood pressure variability (SBPV) was independently associated with an increased risk for all-cause mortality.

  • Morphine Underused for End-of-Life Dyspnea in the Emergency Department Compared with Inpatient Care Among 250 patients presenting to the emergency department (ED) with dyspnea at the end of life, 15.2% received morphine in the ED, whereas 68% received it during subsequent inpatient care. Patients with lung cancer or a do-not-resuscitate order were more likely to receive morphine in the ED, but its use was not associated with reduced survival.

  • Present state and future of screening for atrial fibrillation: a state-of-the-art review Atrial fibrillation is the most common arrhythmia and is a leading cause of stroke and heart failure yet often remains undiagnosed. Screening has been proposed to identify asymptomatic AF and initiate preventive treatment, but evidence for reduction in hard clinical endpoints such as stroke and heart failure remains inconclusive.

  • Levosimendan versus dobutamine in acute decompensated heart failure: systematic review and meta-analysis of randomised controlled trials Acute decompensated heart failure with reduced ejection fraction often requires inotropic support. While dobutamine is commonly used, its safety and efficacy remain debated. Levosimendan has emerged as a potential alternative, with distinct pharmacological properties.

  • Cardiovascular Benefits of Semaglutide in SELECT Trial Not Fully Explained by Weight Loss and Other Improvements In adults with obesity and established cardiovascular disease (CVD), semaglutide was associated with improvements in several risk factors. However, those changes only accounted for part of the reduced risk for major adverse cardiovascular events (MACE) noted in the SELECT trial.

Partners

  • The Department of Health in Moscow
  • The State Committee on Health
  • Silicea-Poligraf, publishing house

Video resource

Channel "Cardioprogress"

Follow us

Top.Mail.Ru

© 2012-2018 Foundation for the advancement of cardiology «Cardioprogress»